Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.


BACKGROUND:Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of this premise. PATIENTS AND METHODS: We retrospectively evaluated the prevalence of actionable alterations in 2 distinct LUSC cohorts totaling 492 patients. A total of 410 consecutive patients with stage 3B or 4 LUSC were tested with a targeted cell-free circulating DNA NGS assay, and 82 patients with LUSC of any stage were tested with a tissue NGS cancer panel. RESULTS:In the overall cohort, 467 patients (94.9%) had a diagnosis of LUSC, and 25 patients (5.1%) had mixed histology with a squamous component. A total of 10.5% of the LUSC subgroup had somatic alterations with therapeutic relevance, including in EGFR (2.8%), ALK/ROS1 (1.3%), BRAF (1.5%), and MET amplification or exon 14 skipping (5.1%). Sixteen percent of patients with mixed histology had an actionable alteration. In the LUSC subgroup, 3 evaluable patients were treated with targeted therapy for an actionable alteration; all of them experienced partial response. CONCLUSION:In this large, real-world LUSC cohort, we observed a clinically significant prevalence of actionable alterations. Accurate local histopathologic assessment in advanced-stage LUSC can be challenging. Further evaluation of the genomic landscape in this setting is warranted to potentially identify underappreciated treatment options.


Clin Lung Cancer


Clinical lung cancer


Lam VK,Tran HT,Banks KC,Lanman RB,Rinsurongkawong W,Peled N,Lewis J,Lee JJ,Roth J,Roarty EB,Swisher S,Talasaz A,Futreal PA,Papadimitrakopoulou V,Heymach JV,Zhang J




Has Abstract


2019-01-01 00:00:00














  • Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.

    abstract::Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib treatment in large, randomized monotherapy trials. In preclinical studies, gefitinib has shown additive and even supra-additive antitumo...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审


    authors: Hammond LA

    更新日期:2003-09-01 00:00:00

  • Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial.

    abstract:INTRODUCTION:For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. PATIENTS AND METHODS:From February 2017 through Februa...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Gerber DE,Hamann HA,Chavez C,Dorsey O,Santini NO,Browning T,Ochoa CD,Adesina J,Natchimuthu VS,Steen E,Zhu H,Lee SJC

    更新日期:2020-07-01 00:00:00

  • Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung Cancer.

    abstract:BACKGROUND:In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study ( identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Neverth...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Repka MC,Kappes J,Thomas M,Bischoff H,Herth F,Heußel CP,Debus J,Steins M,Rieken S

    更新日期:2017-07-01 00:00:00

  • Patients with lung cancer with metachronous or synchronous gastric cancer.

    abstract:BACKGROUND:There are few reports of treatment and outcome for patients with metachronous or synchronous lung and gastric cancers. To evaluate them, we conducted a retrospective study. PATIENTS AND METHODS:The medical records of patients with lung cancer who previously or simultaneously had gastric cancer seen in our d...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Kurishima K,Satoh H,Kagohashi K,Homma S,Nakayama H,Ohara G,Ishikawa H,Hizawa N

    更新日期:2009-11-01 00:00:00

  • Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review.

    abstract::Both gemcitabine and carboplatin have demonstrated activity in advanced non small-cell lung cancer. The combination of gemcitabine and cisplatin has demonstrated equivalent or superior efficacy to other commonly used agents and two-drug combinations, and a recent Eastern Cooperative Oncology Group trial suggested that...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Masters GA

    更新日期:2000-12-01 00:00:00

  • Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.

    abstract:INTRODUCTION:The objective of this study was to present the outcomes of moderately hypofractionated helical intensity-modulated radiation therapy (HT) with/without simultaneous integrated boost (SIB) on fluorodeoxyglucose-positron emission tomography (FDG-PET) positive areas (gross tumor volume [GTV]-PET) for patients ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Fodor A,Broggi S,Incerti E,Dell'Oca I,Fiorino C,Samanes Gajate AM,Pasetti M,Cattaneo MG,Passoni P,Gianolli L,Calandrino R,Picchio M,Di Muzio N

    更新日期:2019-01-01 00:00:00

  • Recurrent bronchial epithelial-myoepithelial carcinoma after local therapy.

    abstract::We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Muslimani AA,Kundranda M,Jain S,Daw HA

    更新日期:2007-05-01 00:00:00

  • Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

    abstract:UNLABELLED:Small observational studies have demonstrated an association between high ERCC1 expression level and poor prognosis in advanced NSCLC treated with platinum-based chemotherapy. This meta-analysis presents pooled estimates of association from 11 studies. High ERCC1 patients had lower response rates and higher ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审


    authors: Roth JA,Carlson JJ

    更新日期:2011-11-01 00:00:00

  • Role of computed tomography fluoroscopy-guided cutting needle biopsy of lung lesions after transbronchial examination resulting in negative diagnosis.

    abstract:INTRODUCTION:Computed tomography (CT)-guided lung biopsy is occasionally used for the lesions that were diagnosed as nonmalignant by transbronchial examination despite the fact that other clinical data suggested those as malignant. The purpose of this study is to evaluate the outcomes of CT fluoroscopy-guided cutting n...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Matsui Y,Hiraki T,Mimura H,Gobara H,Inoue D,Iishi T,Toyooka S,Kanazawa S

    更新日期:2011-01-01 00:00:00

  • Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.

    abstract::Randomized clinical trials (RCTs) of concurrent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) plus chemotherapy for unselected patients with advanced non-small-cell lung cancer (NSCLC) produced negative results. Intercalated administration could avoid the reduction of chemotherapy activity du...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,meta分析,评审


    authors: La Salvia A,Rossi A,Galetta D,Gobbini E,De Luca E,Novello S,Di Maio M

    更新日期:2017-01-01 00:00:00

  • Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).

    abstract:BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

    更新日期:2013-11-01 00:00:00

  • ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.

    abstract:INTRODUCTION:Platinum-based chemotherapy is besides the standard antifolate therapy with pemetrexed, the cornerstone for treatment of patients with malignant pleural mesothelioma (MPM), and its efficacy depends on several DNA repair enzymes. Therefore, these enzymes could be biomarkers for "tailoring" chemotherapy. Thi...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Ting S,Mairinger FD,Hager T,Welter S,Eberhardt WE,Wohlschlaeger J,Schmid KW,Christoph DC

    更新日期:2013-09-01 00:00:00

  • Total videothoracoscopic lobectomy versus open thoracotomy for early-stage non small-cell lung cancer.

    abstract::Lobectomy remains the standard procedure for early-stage non small-cell lung cancer (NSCLC). Advances in minimally invasive surgery allow lobectomy to be performed by videothoracoscopy (VATSLOBE). The objective of this study was to compare open thoracotomy (OPENLOBE) to VATSLOBE in the treatment of early-stage NSCLC. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Luketich JD,Meehan MA,Landreneau RJ,Christie NA,Close JM,Ferson PF,Keenan RJ,Belani CP

    更新日期:2000-08-01 00:00:00

  • Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.

    abstract:INTRODUCTION:Real-world data on current treatment practices for non-small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. PATIENTS AND METHODS:This retrospective cohort study identified patients ≥ 65 years old in the Surveillance, Epidemiology, a...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Arunachalam A,Li H,Bittoni MA,Camacho R,Cao X,Zhong Y,Lubiniecki GM,Carbone DP

    更新日期:2018-09-01 00:00:00

  • A phase II study of topotecan in patients with relapsed small-cell lung cancer.

    abstract::An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Takeda K,Negoro S,Sawa T,Nakagawa K,Kawahara M,Isobe T,Kudoh S,Masuda N,Niitani H,Fukuoka M

    更新日期:2003-01-01 00:00:00

  • Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.

    abstract:BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Gong Z,Chen J,Cheng JN,Sun C,Jia Q,Diao X,Zhu B

    更新日期:2018-09-01 00:00:00

  • Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

    abstract:BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Connolly GC,Menapace L,Safadjou S,Francis CW,Khorana AA

    更新日期:2013-11-01 00:00:00

  • Pathological examination and the reporting of lung cancer specimens.

    abstract::The Lung Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative first met in January of 1994. Included in the membership were three pathologists who, with the other members of the DSG, felt that a useful contribution to the work of the group would be a recommendation on standardized ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Chamberlain DW,Wenckebach GF,Alexander F,Fraser RS,Kolin A,Newman T

    更新日期:2000-05-01 00:00:00

  • Cooperative group research endeavors in small-cell lung cancer: current and future directions.

    abstract::The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...

    journal_title:Clinical lung cancer



    authors: Sangha R,Lara PN Jr,Adjei AA,Baas P,Choy H,Gaspar LE,Goss G,Saijo N,Schiller JH,Vokes EE,Gandara DR

    更新日期:2009-09-01 00:00:00

  • Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.

    abstract:BACKGROUND:Limited data is available on comorbidity assessment in patients with lung cancer. The present prospective study assessed the prevalence and association of the Charlson comorbidity index (CCI) and simplified comorbidity score (SCS) with clinical outcomes in patients with newly diagnosed lung cancer undergoing...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Singh N,Singh PS,Aggarwal AN,Behera D

    更新日期:2016-05-01 00:00:00

  • Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.

    abstract::There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审


    authors: Carbone DP,Felip E

    更新日期:2011-09-01 00:00:00

  • Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Li

    abstract:BACKGROUND:In advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) patients whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors (TKIs), liquid biopsy (LB) is routinely used to evaluate the presence of EGFR T790M as an acquired...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Minari R,Mazzaschi G,Bordi P,Gnetti L,Alberti G,Altimari A,Gruppioni E,Sperandi F,Parisi C,Guaitoli G,Bettelli S,Longo L,Bertolini F,Pagano M,Bonelli C,Tagliavini E,Nicoli D,Ubiali A,Zangrandi A,Trubini S,Proietto

    更新日期:2020-09-01 00:00:00

  • Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

    abstract:BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

    更新日期:2015-09-01 00:00:00

  • Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.

    abstract:BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Qin A,Lusk E,Daignault-Newton S,Schneider BJ

    更新日期:2019-07-01 00:00:00

  • Clinical significance of downstaging in patients with limited-disease small-cell lung cancer.

    abstract:BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

    更新日期:2014-03-01 00:00:00

  • Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.

    abstract:INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

    更新日期:2016-01-01 00:00:00

  • Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.

    abstract::Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审


    authors: Tsao AS,Mehran R,Roth JA

    更新日期:2009-01-01 00:00:00

  • Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.

    abstract:BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Handa Y,Tsutani Y,Shiroma N,Kai Y,Mimae T,Miyata Y,Takeshima Y,Arihiro K,Okada M

    更新日期:2020-07-01 00:00:00

  • Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.

    abstract::Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

    更新日期:2004-03-01 00:00:00

  • The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.

    abstract::After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there has finally been a therapeutic advance. The combination of a platinum chemotherapy, etoposide, and an immune checkpoint inhibitor has yielded overall survival benefits in two successive phase 3 trials. Unfortunately, these trials o...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章


    authors: Friedlaender A,Liu SV,Passaro A,Metro G,Banna G,Addeo A

    更新日期:2020-11-01 00:00:00